贝前列素钠联合免疫抑制剂治疗原发性肾病综合征的疗效和安全性评价

doi:10.13481/j.1671-587x.20180631

吉林大学学报(医学版) ›› 2018, Vol. 44 ›› Issue (06): 1291-1297.doi: 10.13481/j.1671-587x.20180631

贝前列素钠联合免疫抑制剂治疗原发性肾病综合征的疗效和安全性评价

王雪婷^1,2, 周广宇¹, 王艺璇¹, 郭莹¹, 尹敏¹, 吴晨¹

1. 吉林大学中日联谊医院肾内科, 吉林长春 130033;
2. 吉林省长春市人民医院肾内科, 吉林长春 130051

收稿日期:2017-10-25 出版日期:2018-11-28 发布日期:2018-11-28
通讯作者: 周广宇,主任医师,硕士研究生导师(Tel:0431-84995080,E-mail:zhougy@jlu.edu.cn) E-mail:zhougy@jlu.edu.cn
作者简介:王雪婷(1990-),女,吉林省松原市人,医师,医学硕士,主要从事肾小球疾病的发病机制、诊断和治疗方面的研究。
基金资助:
国家自然科学基金面上项目资助课题（81370810）；吉林省科技厅自然科学基金资助课题（20160101059JC）；吉林大学中日联谊医院横向课题资助课题（2017YX301）

Efficacy and evaluation on safety of beraprost sodium combined with immunosuppressor in treatment of primary nephrotic syndrome

WANG Xueting^1,2, ZHOU Guangyu¹, WANG Yixuan¹, GUO Ying¹, YIN Min¹, WU Chen¹

1. Department of Nephrology, China-Japan Union Hospital, Jilin University, Changchun 130033, China;
2. Department of Nephrology, People's Hospital, Changchun City, Jilin Province, Changchun 130051, China

Received:2017-10-25 Online:2018-11-28 Published:2018-11-28

摘要/Abstract

摘要： 目的：探讨贝前列素钠（BPS）联合糖皮质激素（GC）和（或）免疫抑制剂治疗原发性肾病综合征（PNS）患者的临床疗效和安全性，为其应用于PNS的治疗提供依据。方法：选取明确诊断为PNS的患者86例，所有患者均应用GC和（或）免疫抑制剂治疗，根据患者意愿选择不同的抗血小板治疗方案，分为应用BPS的BPS组（n=42）和应用双嘧达莫或阿司匹林的对照组（n=44）。分析2组患者治疗前后相关实验室指标的差异，并比较2组患者治疗有效率、并发症和药物不良反应发生率。结果：与对照组比较，治疗1和6个月时BPS组患者尿蛋白水平明显降低（P<0.05），血清白蛋白（ALB）水平明显升高（P<0.05）；治疗3、6和12个月时，BPS组患者纤维蛋白原（FIB）水平和D-二聚体（DD）水平明显降低（P<0.05或P<0.01）。与对照组比较，治疗1个月时BPS组患者收缩压（SBP）和舒张压（DBP）明显降低（P<0.05）。治疗6个月时BPS组患者总有效率和总胆固醇（TC）水平高于对照组（P<0.05）。与对照组比较，BPS组中基础血压正常患者血压升高发生率明显降低（P<0.05），头晕和头痛发生率明显升高（P<0.05）。结论：BPS联合GC和（或）免疫抑制剂治疗PNS患者安全性较高，优于传统抗血小板药物。

关键词: 原发性肾病综合征, 贝前列素钠, 糖皮质激素, 免疫抑制剂

Abstract: Objective: To explore the clinical efficacy and safety of beraprost sodium (BPS) combined with glucocorticoid (GC) and(or) immunosuppressive agents in the treatment of the patients with primary nephrotic syndrome (PNS),and to provide evidence for its application in the treatment of PNS.Methods: Eighty-six patients diagnosed as PNS definitely were selected.They were treated with GC and(or) immunosuppressive agents and were divided into BPS group (administrated with BPS, n=42) and control group (administrated with dipyridamole or aspirin,n=44) according to their willing to the acceptance of different anti-platelet treatment regimens. The relevant laboratory indexes of the patients in two groups before and after treatment were analyzed, and the effective rate,incidence of complications and drug adverse reactions of the patients in two groups were compared.Results: Compared with control group, the urinary protein levels of the patients in BPS group at the 1st and 6th months after treatment were significantly decresed(P<0.05) and the serum albumin (ALB) levels of the patients in BPS group were significantly increased (P<0.05); the levels of fibrinogen (FIB) and D-dimer (DD) of the patients in BPS group at the 3rd, 6th and 12th months after treatment were significantly decreased (P<0.05 or P<0.01). Compared with control group, the systolic blood pressure(SBP)and diastolic blood pressure (DBP) of the patients in BPS group at the 1st month after treatment were decreased significantly (P<0.05).The cholesterol (TC) level and total effective rate of the patients in BPS group at the 6th month after treatment were higher than those in control group (P<0.05). Compared with control group, the incidence of elevation of blood pressure of the patients with normal basal blood pressure in BPS group was significantly decreased(P<0.05);the incidence of headache and dizziness was significantly increased(P<0.05).Conclusion: The safety of BPS combined with GC and(or)immunosuppressive agents in treating the PNS patients is higher and superior to the conventional antiplatelet agents.

Key words: primary nephrotic syndrome, beraprost sodium, glucocorticoid, immunosuppressive

中图分类号:

R692.6

王雪婷, 周广宇, 王艺璇, 郭莹, 尹敏, 吴晨. 贝前列素钠联合免疫抑制剂治疗原发性肾病综合征的疗效和安全性评价[J]. 吉林大学学报(医学版), 2018, 44(06): 1291-1297.

WANG Xueting, ZHOU Guangyu, WANG Yixuan, GUO Ying, YIN Min, WU Chen. Efficacy and evaluation on safety of beraprost sodium combined with immunosuppressor in treatment of primary nephrotic syndrome[J]. Journal of Jilin University(Medicine Edition), 2018, 44(06): 1291-1297.

参考文献

[1] 王海燕.肾脏病学[M]. 3版. 北京:人民卫生出版社, 2008:269-270, 940-948.
[2] 韩世盛, 卢嫣, 王怡. 前列腺素E1治疗原发性肾病综合征的系统评价[J]. 中国中西医结合肾病杂志, 2014, 15(8):721-724.
[3] Cooper LT. Beraprost for the treatment of intermittent claudication[J]. J Am CollCardiol, 2003, 41(10):1687-1689.
[4] 中国成人肾病综合征免疫抑制治疗专家组.中国成人肾病综合征免疫抑制治疗专家共识[J]. 中华肾脏病杂志, 2014,30(6):467-474.
[5] Awsakulsutthi S, Punpho K, Mamom J, et al. Beraprost sodium for chronic diabetic foot ulcer:a randomized controlled trial in thammasat university hospital[J]. Ann Vasc Dis, 2014, 7(1):40-45.
[6] Guan J, Long L, Chen YQ, et al. Effects of beraprostsodium on renal function and inflammatory factors of rats withdiabetic nephropathy[J]. Genet Mol Res, 2014,13(2):4154-4158.
[7] Watanabe M, Nakashima H, Mochizuki S, et al. Amelioration of diabetic nephropathy in OLETF rats by prostaglandin I2 analog, beraprost sodium[J]. Am J Nephrol, 2009, 30(1):1-11.
[8] Ohba Y, Matsuyama Y, Suzuki K, et al. Beraprost improves renal function and decreases uremic toxin in renal insufficiency[J]. Nihon JinzoGakkai Shi, 2015,57:487.
[9] Takenaka, M, Iio A, Sato R, et al. A double-blind, placebo-controlled, multicenter, prospective randomized study of beraprost sodium treatment for cats with chronic kidney disease[J]. J Vet Intern Med, 2018, 32(1):236-248.
[10] Shimamura M, Miyakawa J, Doi M, et al. The pharmacokinetics of beraprost sodium following single oral administration to subjects with impaired kidney function[J]. J Clin Pharmacol, 2017, 57(4):524-535.
[11] Koyama A, Fujita T, Gejyo F, et al. Orally active prostacyclin analogue beraprost sodium in patients with chronic kidney disease:a randomized, double-blind, placebo-controlled, phase Ⅱ dose finding trial[J]. BMC Nephrol, 2015, 16:165.
[12] Peng L, Li J, Xu Y, et al. The protective effect of beraprost sodium on diabetic nephropathy by inhibiting inflammation and p38 MAPK signaling pathway in high-fat diet/streptozotocin-induced diabetic rats[J]. Int J Endocrinol, 2016, 2016:1690474.
[13] Vaziri ND. Molecular mechanisms of lipid disorders in nephroticsyndrome[J]. Kidney Int, 2003, 63(5):1964-1976.
[14] Hillege HL, Fidler V, Diercks GF, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population[J]. Circulation, 2002, 106(14):1777-1782.
[15] Cushman M, Folsom AR, Wang L, et al. Fibrin fragment D-dimer and the risk of future venous thrombosis[J]. Blood, 2003, 101(4):1243-1248.
[16] 陈怡, 万建新, 江德文, 等. 前列地尔联合贝前列素钠序贯治疗慢性肾脏病[J]. 南方医科大学学报, 2013, 33(10):1521-1524.
[17] Hiraishi H, Maeda M, Sasai T, et al. Strategy to manage low dose aspirin-induced gastrointestinal injury[J]. Nippon Rinsho, 2011, 69(2):369-375.
[18] Yamada M, Sasaki R, Sato N, et al. Amelioration by beraprost sodium, a prostacyclin analogue, of established renal dysfunction in rat glomerulonephritis model[J]. Eur J Pharmacol, 2002, 449(1/2):167-176.
[19] Nootheti S, Bielory L. Risk of cataracts and glaucoma with inhaled steroid use in children[J]. Compr Ophthalmol Update, 2006, 7(1):31-39.
[20] Goto Y, Yamaguchi S, Tamura M, et al. A prostacyclin analog prevents the regression of renal microvascular network by inhibiting mitochondria-dependent apoptosis in the kidney of rat progressive glomerulonephritis[J]. Prostaglandins Other Lipid Mediat, 2014, 112:16-26.
[21] 鱼建平.缬沙坦联合贝前列素钠对高血压合并早期肾损伤患者肾功能、凝血功能以及内皮损伤的影响[J].海南医学院学报, 2016, 22(24):58-61.

贝前列素钠联合免疫抑制剂治疗原发性肾病综合征的疗效和安全性评价

Efficacy and evaluation on safety of beraprost sodium combined with immunosuppressor in treatment of primary nephrotic syndrome

RichHTML

PDF (PC)

赞

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 11

Metrics

本文评价

推荐阅读 10

[1]	司延芳, 莫冉冉, 李慧婷, 宋鹏, 李明娴. 艾滋病伴肾上腺皮质功能减退症1例报告并文献复习[J]. 吉林大学学报(医学版), 2017, 43(05): 1030-1033.
[2]	张彦秋, 王春生, 王坤正, 蒋朝龙. 长期应用糖皮质激素对大鼠骨组织中HMGB1、RAGE、OPG和RANKL表达的影响[J]. 吉林大学学报(医学版), 2015, 41(05): 907-913.
[3]	何婧, 戚迪, 王导新. 胰岛素通过mTORC2/SGK1途径上调肺泡上皮钠通道α亚基的作用机制[J]. 吉林大学学报(医学版), 2015, 41(04): 716-720.
[4]	李丹\|袁海波\|彭丽萍\|华树成. 支气管哮喘的病理学特征分类及其对糖皮质激素的反应[J]. J4, 2010, 36(6): 1130-1133.
[5]	左凌云, 赵伟, 赵红, 俞海英, 孙薇薇. H1N1患者疾病早期CD4+T细胞减少及其临床意义[J]. J4, 2010, 36(5): 979-981.
[6]	赵凯姝, 张云峰, 郭世杰, 黄艳智, 高航, 鲁继荣. 白细胞介素15在小鼠支气管哮喘发病中的作用[J]. J4, 2009, 35(5): 832-836.
[7]	张云峰, 赵凯姝, 张波, 孙萌, 鲁继荣. 哮喘鼠白细胞介素23水平变化及其作用机制[J]. J4, 2009, 35(4): 681-684.
[8]	寇长贵，吕晓珍，齐霁，谢冰，于雅琴. 雷公藤多甙联合糖皮质激素对肾病综合征疗效的Meta分析 [J]. J4, 2008, 34(4): 671-675.
[9]	白丽，庞传超，徐阳春，马英智. 天疱疮的合理治疗及预后影响因素分析[J]. J4, 2007, 33(4): 754-756.
[10]	李波,宁宇，杨明堂，王志，杨平，刘娅. 吸入糖皮质激素治疗儿童哮喘的有效性和安全性的Meta-分析[J]. J4, 2006, 32(5): 883-887.
[11]	华树成，李晓荣，谭岩，方艳秋，宋薇薇. SARS患者肾上腺糖皮质激素治疗前后临床表现及胸部X线影像变化[J]. J4, 2004, 30(4): 621-622.